Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Current Hypertension Reports
Published in: Current Hypertension Reports 2/2010

01-04-2010

Oxidative Stress and Hypertension: Current Concepts

Authors: Ana M. Briones, Rhian M. Touyz

Published in: Current Hypertension Reports | Issue 2/2010

Login to get access

Abstract

Hypertension is a major contributor to the development of renal failure, cardiovascular disease, and stroke. These pathologies are associated with vascular functional and structural changes including endothelial dysfunction, altered contractility, and vascular remodeling. Central to these phenomena is oxidative stress. Factors that activate pro-oxidant enzymes, such as NADPH oxidase, remain poorly defined, but likely involve angiotensin II, mechanical stretch, and inflammatory cytokines. Reactive oxygen species influence vascular, renal, and cardiac function and structure by modulating cell growth, contraction/dilatation, and inflammatory responses via redox-dependent signaling pathways. Compelling data from molecular and cellular experiments, together with animal studies, implicate a role for oxidative stress in hypertension. However, the clinical evidence is still controversial. This review provides current insights on the mechanisms of the generation of reactive oxygen species and the vascular effects of oxidative stress and discusses the significance of oxidative damage in experimental and clinical hypertension.
Literature
1.
2.
Forbes JM, Coughlan MT, Cooper ME: Oxidative stress as a major culprit in kidney disease in diabetes. Diabetes 2008, 57:1446–1454.CrossRefPubMed
3.
Huang PL: eNOS, metabolic syndrome and cardiovascular disease. Trends Endocrinol Metab 2009, 20:295–302.CrossRefPubMed
4.
Xu S, He Y, Vokurkova M, Touyz RM: Endothelial cells negatively modulate reactive oxygen species generation in vascular smooth muscle cells: role of thioredoxin. Hypertension 2009, 54:427–433.CrossRefPubMed
5.
Allen CL, Bayraktutan U: Oxidative stress and its role in the pathogenesis of ischaemic stroke. Int J Stroke 2009, 4:461–470.CrossRefPubMed
6.
Touyz RM: Molecular and cellular mechanisms in vascular injury in hypertension: role of angiotensin II. Curr Opin Nephrol Hypertens 2005, 14:125–131.PubMedCrossRef
7.
Guzik TJ, Korbut R, Adamek-Guzik T: Nitric oxide and superoxide in inflammation and immune regulation. J Physiol Pharmacol 2003, 54:469–487.PubMed
8.
Haddad JJ: Antioxidant and prooxidant mechanisms in the regulation of redox(y)-sensitive transcription factors. Cell Signal 2002, 14:879–897.CrossRefPubMed
9.
Ardanaz N, Pagano PJ: Hydrogen peroxide as a paracrine vascular mediator: regulation and signaling leading to dysfunction. Exp Biol Med 2006, 231:237–251.
10.
Liochev SI, Fridovich I: The effects of superoxide dismutase on H2O2 formation. Free Radic Biol Med 2007, 42:1465–1469.CrossRefPubMed
11.
Suvorava T, Kojda G: Reactive oxygen species as cardiovascular mediators: lessons from endothelial-specific protein overexpression mouse models. Biochem Biophys Acta 2009, 1787:802–810.CrossRefPubMed
12.
Brown DI, Griendling KK: Nox proteins in signal transduction. Free Radic Biol Med 2009, 47:1239–1253.CrossRefPubMed
13.
Gillespie MN, Pastukh V, Ruchko MV: Oxidative DNA modifications in hypoxic signaling. Ann N Y Acad Sci 2009, 1177:140–150.CrossRefPubMed
14.
Ebrahimian T, Touyz RM: Thioredoxin in vascular biology: role in hypertension. Antioxid Redox Signal 2008, 10:1127–1136.CrossRefPubMed
15.
16.
Vaziri ND: Roles of oxidative stress and antioxidant therapy in chronic kidney disease and hypertension. Curr Opin Nephrol Hypertens 2004, 13:93–99.CrossRefPubMed
17.
Addabbo F, Montagnani M, Goligorsky MS: Mitochondria and reactive oxygen species. Hypertension 2009, 53:885–892.CrossRefPubMed
18.
Peterson JR, Sharma RV, Davisson RL: Reactive oxygen species in the neuropathogenesis of hypertension. Curr Hypertens Rep 2006, 8:232–241.CrossRefPubMed
19.
Ponnuchamy B, Khalil RA: Cellular mediators of renal vascular dysfunction in hypertension. Am J Physiol Regul Integr Comp Physiol 2009, 296:R1001–R1018.PubMed
20.
Alp NJ, Paolocci N, Champion HC, Kass DA: Reversal of cardiac hypertrophy and fibrosis from pressure overload by tetrahydrobiopterin: efficacy of recoupling nitric oxide synthase as a therapeutic strategy. Circulation 2008, 117:2626–2636.CrossRefPubMed
21.
•Hulsmans M, Holvoet P: The vicious circle between oxidative stress and inflammation in atherosclerosis. J Cell Mol Med 2009 Nov 28 (Epub ahead of print). This is an up-to-date review on the association between ROS and inflammation.
22.
Castro MM, Rizzi E, Rodrigues GJ, et al.: Antioxidant treatment reduces matrix metalloproteinase-2-induced vascular changes in renovascular hypertension. Free Radic Biol Med 2009, 46:1298–1307.CrossRefPubMed
23.
Tabet F, Savoia C, Schiffrin EL, Touyz RM: Differential calcium regulation by hydrogen peroxide and superoxide in vascular smooth muscle cells from spontaneously hypertensive rats. J Cardiovasc Pharmacol 2004, 44:200–208.CrossRefPubMed
24.
Touyz RM, Chen X, Tabet F, et al.: Expression of a functionally active gp91phox-containing neutrophil-type NAD(P)H oxidase in smooth muscle cells from human resistance arteries: regulation by angiotensin II. Circ Res 2002, 90:1205–1213.CrossRefPubMed
25.
••Yang G, Wu L, Jiang B, et al.: H2S as a physiologic vasorelaxant: hypertension in mice with deletion of cystathionine gamma-lyase. Science 2008, 322:587–590. This excellent study demonstrates that H 2 S is a potent vasodilator and that deficiency of H 2 S is associated with hypertension.CrossRefPubMed
26.
Suzuki H, DeLano FA, Parks DA, et al.: Xanthine oxidase activity associated with arterial blood pressure in spontaneously hypertensive rats. Proc Natl Acad Sci U S A 1998, 95:4754–4759.CrossRefPubMed
27.
Adlam D, Bendall JK, De Bono JP, et al.: Relationships between nitric oxide-mediated endothelial function, eNOS coupling and blood pressure revealed by eNOS-GTP cyclohydrolase 1 double transgenic mice. Exp Physiol 2007, 92:119–126.CrossRefPubMed
28.
Victor VM, Apostolova N, Herance R, et al.: Oxidative stress and mitochondrial dysfunction in atherosclerosis: mitochondria-targeted antioxidants as potential therapy. Curr Med Chem 2009, 16:4654–4667.CrossRefPubMed
29.
Viel EC, Benkirane K, Javeshghani D, et al.: Xanthine oxidase and mitochondria contribute to vascular superoxide anion generation in DOCA-salt hypertensive rats. Am J Physiol Heart Circ Physiol 2008, 295:H281–H288.CrossRefPubMed
30.
Spiekermann S, Schenk K, Hoeper MM: Increased xanthine oxidase activity in idiopathic pulmonary arterial hypertension. Eur Respir J 2009, 34:276–280.CrossRefPubMed
31.
Mervaala EM, Cheng ZJ, Tikkanen I, et al.: Endothelial dysfunction and xanthine oxidoreductase activity in rats with human renin and angiotensinogen genes. Hypertension 2001, 37:414–418.PubMed
32.
Laakso J, Mervaala E, Himberg JJ, et al.: Increased kidney xanthine oxidoreductase activity in salt-induced experimental hypertension. Hypertension 1998, 32:902–906.PubMed
33.
Sánchez-Lozada LG, Tapia E, Soto V, et al.: Treatment with the xanthine oxidase inhibitor febuxostat lowers uric acid and alleviates systemic and glomerular hypertension in experimental hyperuricaemia. Nephrol Dial Transplant 2008, 23:1179–1185.CrossRefPubMed
34.
Kanbay M, Ozkara A, Selcoki Y, et al.: Effect of treatment of hyperuricemia with allopurinol on blood pressure, creatinine clearence, and proteinuria in patients with normal renal functions. Int Urol Nephrol 2007, 39:1227–1233.CrossRefPubMed
35.
Feig DI, Soletsky B, Johnson RJ: Effect of allopurinol on blood pressure of adolescents with newly diagnosed essential hypertension: a randomized trial. JAMA 2008, 300:924–932.CrossRefPubMed
36.
Yang J, Kamide K, Kokubo Y, et al.: Associations of hypertension and its complications with variations in the xanthine dehydrogenase gene. Hypertens Res 2008, 31:931–940.CrossRefPubMed
37.
Vásquez-Vivar J: Tetrahydrobiopterin, superoxide, and vascular dysfunction. Free Radic Biol Med 2009, 47:1108–1119.CrossRefPubMed
38.
Vasquez-Vivar J, Kalyanaraman B, Martasek P, et al.: Superoxide generation by endothelial nitric oxide synthase: the influence of cofactors. Proc Natl Acad Sci U S A 1998, 95:9220–9225.CrossRefPubMed
39.
Gao YT, Roman LJ, Martásek P, et al.: Oxygen metabolism by endothelial nitric-oxide synthase. J Biol Chem 2007, 282:28557–28565.CrossRefPubMed
40.
Cosentino F, Patton S, d’Uscio LV, et al.: Tetrahydrobiopterin alters superoxide and nitric oxide release in prehypertensive rats. J Clin Invest 1998, 101:1530–1537.CrossRefPubMed
41.
Ozaki M, Kawashima S, Yamashita T, et al.: Overexpression of endothelial nitric oxide synthase attenuates cardiac. hypertrophy induced by chronic isoproterenol infusion. Circ J 2002, 66:851–856.CrossRefPubMed
42.
Landmesser U, Dikalov S, Price SR, et al.: Oxidation of tetrahydrobiopterin leads to uncoupling of endothelial cell nitric oxide synthase in hypertension. J Clin Invest 2003, 111:1201–1209.PubMed
43.
Lee CK, Han JS, Won KJ, et al.: Diminished expression of dihydropteridine reductase is a potent biomarker for hypertensive vessels. Proteomics 2009, 9:4851–4858.CrossRefPubMed
44.
Ceylan-Isik AF, Guo KK, Carlson EC, et al.: Metallothionein abrogates GTP cyclohydrolase I inhibition-induced cardiac contractile and morphological defects: role of mitochondrial biogenesis. Hypertension 2009, 53:1023–1031.CrossRefPubMed
45.
Sullivan JC, Pollock JS: Coupled and uncoupled NOS: separate but equal? Uncoupled NOS in endothelial cells is a critical pathway for intracellular signaling. Circ Res 2006, 98:717–719.CrossRefPubMed
46.
Katusic ZS, d’Uscio LV, Nath KA: Vascular protection by tetrahydrobiopterin: progress and therapeutic prospects. Trends Pharmacol Sci 2009, 30:48–54.CrossRefPubMed
47.
••Leto TL, Morand S, Hurt D, Ueyama T: Targeting and regulation of reactive oxygen species generation by Nox family NADPH oxidases. Antioxid Redox Signal 2009, 11(10):2607–2619. This is an excellent overview of the Nox isoforms and their putative functions.CrossRefPubMed
48.
Bedard K, Krause KH: The NOX family of ROS-generating NADPH oxidases: physiology and pathophysiology. Physiol Rev 2007, 87:245–313.CrossRefPubMed
49.
Brandes RP, Schröder K: Differential vascular functions of Nox family NADPH oxidases. Curr Opin Lipidol 2008, 19:513–518.CrossRefPubMed
50.
Sumimoto H: Structure, regulation and evolution of Nox-family NADPH oxidases that produce reactive oxygen species. FEBS J 2008, 275:3249–3277.CrossRefPubMed
51.
Nauseef WM: Biological roles for the NOX family NADPH oxidases. J Biol Chem 2008, 283:16961–16965.CrossRefPubMed
52.
Guzik TJ, Griendling KK: NADPH oxidases: molecular understanding finally reaching the clinical level? Antioxid Redox Signal 2009, 11:2365–2370.CrossRefPubMed
53.
Lassegue B, Clempus RE: Vascular NAD(P)H oxidases: specific features, expression, and regulation. Am J Physiol Regul Integr Comp Physiol 2003, 285:R277–R297.PubMed
54.
Sedeek M, Hébert RL, Kennedy CR, et al.: Molecular mechanisms of hypertension: role of Nox family NADPH oxidases. Curr Opin Nephrol Hypertens 2009, 18:122–127.CrossRefPubMed
55.
Li JM, Shah AM: Intracellular localization and preassembly of the NAD(P)H oxidase complex in cultured endothelial cells. J Biol Chem 2002, 277:19952–19960.CrossRefPubMed
56.
Orosz Z, Csiszar A, Labinskyy N, et al.: Cigarette smoke-induced proinflammatory alterations in the endothelial phenotype: role of NAD(P)H oxidase activation. Am J Physiol Heart Circ Physiol 2007, 292:H130–H139.CrossRefPubMed
57.
•Lyle AN, Deshpande NN, Taniyama Y, et al.: Poldip2, a novel regulator of Nox4 and cytoskeletal integrity in vascular smooth muscle cells. Circ Res 2009, 105:249–259. This interesting study identifies a new regulator of Nox4 that also interacts with the cytoskeleton.CrossRefPubMed
58.
Touyz RM, Schiffrin EL: Increased generation of superoxide by angiotensin II in smooth muscle cells from resistance arteries of hypertensive patients: role of phospholipase D-dependent NAD(P)H oxidase-sensitive pathways. J Hypertens 2001, 19:1245–1254.CrossRefPubMed
59.
Landmesser U, Cai H, Dikalov S, et al.: Role of p47(phox) in vascular oxidative stress and hypertension caused by angiotensin II. Hypertension 2002, 40:511–555.CrossRefPubMed
60.
Matsuno K, Yamada H, Iwata K, et al.: Nox1 is involved in angiotensin II-mediated hypertension: a study in Nox1-deficient mice. Circulation 2005, 112:2677–2685.CrossRefPubMed
61.
Dikalova A, Clempus R, Lassegue B, et al.: Nox1 overexpression potentiates angiotensin II-induced hypertension and vascular smooth muscle hypertrophy in transgenic mice. Circulation 2005, 112:2668–2676.CrossRefPubMed
62.
Touyz RM, Mercure C, He Y, et al.: Angiotensin II-dependent chronic hypertension and cardiac hypertrophy are unaffected by gp91phox-containing NADPH oxidase. Hypertension 2005, 45:530–537.CrossRefPubMed
63.
Jung O, Schreiber JG, Geiger H, et al.: gp91phox-containing NAD(P)H oxidase mediates endothelial dysfunction in renovascular hypertension. Circulation 2004, 109:1795–1801.CrossRefPubMed
64.
Zhou MS, Adam AG, Jaimes EA, Raij L: In salt-sensitive hypertension, increased superoxide production is linked to functional upregulation of angiotensin II. Hypertension 2003, 42:945–951.CrossRefPubMed
65.
Peterson JR, Burmeister MA, Tian X, et al.: Genetic silencing of Nox2 and Nox4 reveals differential roles of these NADPH oxidase homologues in the vasopressor and dipsogenic effects of brain angiotensin II. Hypertension 2009, 54:1106–1114.CrossRefPubMed
66.
Wilcox CS: Oxidative stress and nitric oxide deficiency in the kidney: a critical link to hypertension? Am J Physiol Regul Integr Comp Physiol 2005, 289:R913–R935.PubMed
67.
Modlinger P, Chabrashvili T, Gill PS, et al.: RNA silencing in vivo reveals role of p22phox in rat angiotensin slow pressor response. Hypertension 2006, 47:238–244.CrossRefPubMed
68.
Adler S, Huang H: Oxidant stress in kidneys of spontaneously hypertensive rats involves both oxidase overexpression and loss of extracellular superoxide dismutase. Am J Physiol Renal Physiol 2004, 287:F907–F913.CrossRefPubMed
69.
Panico C, Luo Z, Damiano S, et al.: Renal proximal tubular reabsorption is reduced in adult spontaneously hypertensive rats: roles of superoxide and Na+/H+ exchanger 3. Hypertension 2009, 54:1291–1297.CrossRefPubMed
70.
••Violi F, Sanguigni V, Carnevale R, et al.: Hereditary deficiency of gp91(phox) is associated with enhanced arterial dilatation: results of a multicenter study. Circulation 2009, 120:1616–1622. This is the first comprehensive clinical study focusing on vascular function in patients deficient in gp91 phox .CrossRefPubMed
71.
Yogi A, Mercure C, Touyz J, et al.: Renal redox-sensitive signaling, but not blood pressure, is attenuated by Nox1 knockout in angiotensin II-dependent chronic hypertension. Hypertension 2008, 51:500–506.CrossRefPubMed
72.
Nambiar S, Viswanathan S, Zachariah B, et al.: Oxidative stress in prehypertension: rationale for antioxidant clinical trials. Angiology 2009, 60:221–234.PubMed
73.
Nabha L, Garbern JC, Buller CL, Charpie JR: Vascular oxidative stress precedes high blood pressure in spontaneously hypertensive rats. Clin Exp Hypertens 2005, 27:71–82.CrossRefPubMed
74.
Sathiyapriya V, Selvaraj N, Nandeesha H, et al.: Association between protein bound sialic acid and high sensitivity C-reactive protein in prehypertension: a possible indication of underlying cardiovascular risk. Clin Exp Hypertens 2008, 30:367–374.CrossRefPubMed
75.
Callera GE, Touyz RM, Teixeira SA, et al.: ETA receptor blockade decreases vascular superoxide generation in DOCA-salt hypertension. Hypertension 2003, 42:811–817.CrossRefPubMed
76.
Chen X, Touyz RM, Park JB, Schiffrin EL: Antioxidant effects of vitamins C and E are associated with altered activation of vascular NADPH oxidase and superoxide dismutase in stroke-prone SHR. Hypertension 2001, 38:606–611.CrossRefPubMed
77.
•Ardanaz N, Yang XP, Cifuentes ME, et al.: Lack of glutathione peroxidase 1 accelerates cardiac-specific hypertrophy and dysfunction in angiotensin II hypertension. Hypertension 2009, 55:116–123. This interesting study demonstrates the importance of glutathione deficiency in cardiac hypertrophy but not in the development of hypertension.CrossRefPubMed
78.
Ward NC, Hodgson JM, Puddey IB, et al.: Oxidative stress in human hypertension: association with antihypertensive treatment, gender, nutrition, and lifestyle. Free Radic Biol Med 2004, 36:226–232.CrossRefPubMed
79.
Moreno MU, San Jose G, Orbe J, et al.: Preliminary characterisation of the promoter of the human p22(phox) gene: identification of a new polymorphism associated with hypertension. FEBS Lett 2003, 542:27–31.CrossRefPubMed
80.
Holowatz LA, Kenney WL: Local ascorbate administration augments NO- and non-NO-dependent reflex cutaneous vasodilation in hypertensive humans. Am J Physiol Heart Circ Physiol 2007, 293:H1090–H1096.CrossRefPubMed
Metadata
Title
Oxidative Stress and Hypertension: Current Concepts
Authors
Ana M. Briones
Rhian M. Touyz
Publication date
01-04-2010
Publisher
Current Science Inc.
Published in
Current Hypertension Reports / Issue 2/2010
Print ISSN: 1522-6417
Electronic ISSN: 1534-3111
DOI
https://doi.org/10.1007/s11906-010-0100-z

Other articles of this Issue 2/2010

Current Hypertension Reports 2/2010 Go to the issue

Literature Alert

Medical Complexity and Hypertension Management

OriginalPaper

Sodium Sensitivity of Blood Pressure in Chinese Populations

OriginalPaper

Carotid Baroreflex Activation: Past, Present, and Future

ReviewPaper

The Obesity Paradox and Cardiovascular Disease

ReviewPaper

Midkine Regulation of the Renin-Angiotensin System

ReviewPaper

Modulation of Pressure-Natriuresis by Renal Medullary Reactive Oxygen Species and Nitric Oxide
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits